The targeting of a novel ligand:receptor dyad, CD200:CD200R, in regulation of tumor growth control has been a primary focus of the work in my laboratory, and again studies in animal models, discussed in depth below, have highlighted the therapeutic potential of such targeting in both solid tumors and B-cell malignancies [12]. This evidence concerns the gene CD200 and neoplasm.